Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

N. Yamazaki



Author of

  • +

    P2.14 - Poster Session 2 - Mesothelioma (ID 196)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Mesothelioma
    • Presentations: 1
    • +

      P2.14-010 - Intrapleural Perfusion Hyperthermo-Chemotherapy with Cisplatin in Patients with Malignant Pleural Mesothelioma. (ID 3360)

      09:30 - 09:30  |  Author(s): N. Yamazaki

      • Abstract

      Background
      For patients with malignant pleural mesothelioma (MPM), intensive local regulations are needed,whether patients will be treated with EPP or not. In order to obtain adequate control of malignant effusion and expect temporary anti-tumor effect, we have introduced intrapleural perfusion hyperthermo-chemotherapy (IPHC) with cisplatin.

      Methods
      Twenty-six patients with MPM underwent IPHC at the time of pleural biopsy with thoracoscope. Hyperthermo(42.5 ℃)-perfusion was performed with cisplatin (80mg/m[2]) during 60 minutes under the general anesthesia. Complications, control of pleural perfusion, treatment followed by IPHC, and survival time, were studied.

      Results
      Median age was 68 years (range, 56-82). Twenyy-four patients were male. Eiteen patients had epitherial, 5 had biphasic,and 3 had sarcomatoid histology. Fifteen had left-sided disease. There were no serious clinical complications associated with this procedure. The pleural effusion was well controlled in all patients. Adjuvant chemotherapies (CT) were performed immediately in 24 patients. Nine patients were treated by EPP after 2 course of CT: One/2/5 year survival rates were 87.5/50.0/37.5 %, respectively. MST was 19.5 months.Seventeen patients were treated by CT (platinum + Pem) : One/2 year survival rates were 81.9/29.8 %, respectively. MST was 14.0 months.

      Conclusion
      IPHC with cisplatin is easy to perform, and relatively safe. This method had brought an ideal pleural adhesion. IPHC may offer excellent local control and good survival for patients with MPM as a part of multi-modality therapy.